A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies
Clinical trial NCT07173595 · RECRUITING
Trial details
- NCT number
- NCT07173595
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-05
- Primary completion
- 2027-12-01
- Enrollment
- 186
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.